 |

|

|
 |
 |
 |
 |
 |
3SBio
Fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China
IPO in May 2015 (HKSE: 1530)
|
AADI Bioscience
Clinical stage biopharmaceutical company developing a nanoparticle albumin-bound mTOR inhibitor based on sirolimus or rapamycin, also known as nab-rapamycin |
Albireo Pharma
Clinical stage biopharma company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other adult liver diseases and disorders
(NASDAQ:ALBO) |
Alpine Immune Sciences
Biotech company developing innovative treatments for patients suffering from cancer and autoimmune/inflammatory diseases
(NASDAQ:ALPN) |
 |
 |

|
 |
 |
 |
 |
 |
AnHeart Therapeutics
Clinical-stage biopharmaceutical company based in China focused on the acquisition, development and commercialization of oncology products |
Apexigen
Clinical-stage biopharmaceutical company focusing on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology |
Arcus Biosciences
Clinical-stage biotechnology company focused on the discovery and development of innovative cancer immunotherapies
IPO in March 2018 (NASDAQ:RCUS) |
Ariagen
Biotech company founded by Decheng Capital to develop a novel class of small molecules as cancer immunotherapies |

|
 |
 |

|
 |
 |
 |
 |
Ark Biosciences
Ark Biosciences is a biotech startup company focusing on innovative drug discovery and development, especially in the respiratory virus field, for world-wide markets |
ARMO Biosciences
Late-stage immuno-oncology company that is developing a pipeline of novel, proprietary products that activate the immune system of cancer patients to recognize and eradicate tumors
Acquired by Eli Lilly in May 2018 |
BeyondSpring
Clinical-stage biopharmaceutical company developing plinabulin, an anti-cancer agent
(NASDAQ:BYSI) |
Bioheng
Biotech company based in China developing universal CAR-T products |
 |
 |
 |
 |
 |
 |
 |
 |
Checkmate Pharmaceuticals
Clinical stage biopharma company that is leveraging its expertise in the field of CpG oligonucleotides to discover and develop immunotherapies designed to increase the efficacy of existing immunotherapies
IPO in August 2020 (NASDAQ: CMPI) |
EpimAb Biotherapeutics
Biopharmaceutical company dedicated to generating novel bi-specific antibody therapeutics based on its proprietary FIT-Ig (Fabs-In-Tandem) platform |
Everest Medicines
Biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia
IPO in October 2020 (HKSE: 1952) |
GRIT Biotechnology
Biotech company developing tumor infiltration lymphocytes immunotherapy for solid tumors
|

|
 |

|

|
 |
 |
 |
 |
Hummingbird Bioscience
Biotech company, with facilities in Singapore and Silicon Valley, focused on applying advances in systems biology to rapidly develop antibodies into successful cancer therapeutics
|
IMPACT Therapeutics
Clinical stage biopharmaceutical company focusing on discovery and development of best-in-class anti-cancer drugs targeting a poly (ADP-ribose) polymerase (PARP) |
KeChow Pharma
Clinical-stage biotech based in China focused on developing small molecules for clinically validated oncology targets |
Kind Pharmaceutical
Clinical stage biopharmaceutical company based in China focusing on discovery and development of best-in-class anemia drugs |
 |
 |

|
 |
 |
 |
 |
 |
LYNK Pharmaceuticals
Preclinical stage biotech comapny focused on researching and developing JAK family small molecules |
Scynexis
Biotech company developing innovative therapies for difficult-to-treat and often life-threatening infections
(NASDAQ:SCYX) |
Terns Pharmaceuticals
Clinical stage biopharma company based in Shanghai and Silicon Valley developing oral, small molecule drugs for nonalcoholic steatohepatitis (NASH), a liver disease |
VelosBio
Biopharma company focused on developing an antibody-drug conjugate of cirmtuzumab, a ROR1 antibody
Acquired by Merck in November 2020 |